Logo
Subscribe Now

All Posts by Date

Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC

Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC

Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC

Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC

Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC

Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC

Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma

Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Lilly Reports Results of Tirzepatide in SURPASS-4 Study for Patients with Type 2 Diabetes

Lilly Reports Results of Tirzepatide in SURPASS-4 Study for Patients with Type 2 Diabetes

Image

Stay Connected

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2021 PharmaShots - All Rights Reserved.